Dr. Ganesh Kumar Ammannaya
5.5K posts

Dr. Ganesh Kumar Ammannaya
@DAmmannaya
Cardiac Surgeon, Medical Researcher & Innovator. Value Equity Investor since 21. Tweets abt Stocks are Educational & NOT Recommendations.







Wave 5 has taken off well since the quoted tweet.


Wave 4 - 50% Retracement of (15,183 to 26,373) works out to 20,778 April 2025 Low - 21,743 These 2 Key SUPPORTS, if 22,283 broken. Wave 5 = Wave 1 = 11,093 31,871 / 32,836 Picture still remains same as before (no change, just delay) in my opinion.


FERMENTA BIOTECH - Interesting Stock Idea that merits further research. (NOT A RECOMMENDATION / NOT INVESTMENT ADVICE, Merely a Stock Idea for further in-depth Study) Currently trading at merely 8 PE on TTM EPS Rs 38.06 (Historical PE - last 10 yrs Mean PE 19.40, Lifetime avg PE 15). ROCE 23%, ROE 24.9% (EBIDTA margin H1 FY26 25.9%) with excellent H1/Q2 FY26 Nos. LATEST Development - (first 2 images) of MAJOR CAPEX. VITAMIN D3 Moat - World leader (among Top 3 & the Only Indian Co) in Vitamin D3 (niche player) Recent PATENT for its plant based (Vegan) Vitamin D3 expected to significantly expand margins as these command much higher premiums (image 3 gives a very rough idea about premium margins), expected to be a Key Growth Driver in core business, also for which CAPEX is primarily planned for this FY26 & FY27. Increasing awareness worldwide about role of Vitamin D3 in virtually every organ system of human body, ill effects of its deficiency such as increased cardiovascular risks, infertility & recent European studies showing improved survival in Cancer patients on Vitamin D3 supplements, apart from proven benefits such as anti-ageing, anti cancer & immunity boosting effects, one of the mainstays in the treatment of osteoporosis (weak bones particularly elderly) etc., augurs well for wide scale use across all geographies. Scale Up in GERMAN Operations - H1 FY26 revenue 34.3 Cr (Up 194% YoY) & EBIDTA 7.7 Cr (Up 103% YoY). - Overall EU share increasing to 29% (from 27%), - US share dropping to 13% (from 15%). - Rest Domestic - 40%, - Others-18% Expanding to Other Vitamins - Vitamins K1 (one of the few global suppliers), Vitamin- fortified Rice (Govt schemes, like in AP) with plans of Vitamin A, E over next 5 yrs. MoU with NIFTEM to establish Centre of excellence for Food Fortification enhancing public nutrition. Additionally, Environmental solutions including Waste WATER management. fermentabiotech.com/environmental-… Co seems to be focusing keenly on this segment as evidenced by further investment of Rs 7.9 Cr more recently in the subsidiary. Result of this increased focus on Environmental Solutions Subsidiary Visible as - H1 Revenue up 127% in H1 FY26 (to 15.1 Cr, from 6.6 Cr YoY). Co has been unlocking Value from Real Estate well. Has excellent LAND BANK primarily in Thane 5.5 acres (apart from Thane One) & 45 acres in Takwe, Pune, alongside steady leasehold income like Thane One. Debt levels cut down more than half from 239 to 112 Cr, with Turnaround Positive Cash Flow. Promoter stake has increased steadily from 59 to 64% over last 2 yrs with No of Retail shareholders coming down from 17 K to 13 K during times of extreme stress for the Co until the recent Turnaround. Technically, C&H with probably a “W” shaped Bottom (256, that’s a DOUBLE BOTTOM, also the Key Support) in the handle seems supportive & Key multi-year resistance being (also ATH) ~450, which it tested 2-3 times in the last 7 yrs. Thus, makes a case for further in-depth research. (NOT A RECOMMENDATION / NOT INVESTMENT ADVICE, Merely a Stock Idea for further Study)

𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗗𝗼𝗺𝗲𝘀𝘁𝗶𝗰 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 must be 𝗥𝗲𝘄𝗮𝗿𝗱𝗲𝗱, 𝗻𝗼𝘁 𝗣𝗲𝗻𝗮𝗹𝗶𝘀𝗲𝗱. I explained in Parliament how Investment in India remains heavily taxed, and why it needs to change.



Proud to be invited to the “INTERNATIONAL CORONARY CONGRESS 2025”, to present my work regarding Rapid Recovery after Heart Bypass (CABG) in NEW YORK, this December.








Tough Markets Undoubtedly - But, Not impossible to Outperform! US moving exactly as per Chart hovering close to the magic 6150, with about 20% or more DECOUPLING wrt to NIFTY, the WORST I have witnessed till date. Whatever may be in store ahead (Scenario 1. Repeat of 2015, which saw a year full of slow painful correction with return of bull in 16-17, or 2. Bottoming in the short term at 21,300-21,700, followed by bull 3. Something else! Nobody can predict, nobody can say anything for sure) But as long term investor, nothing changes really! Just Need to stick to OUR WINNING WAYS!

Successful Investment also needs plentiful luck. Latest example-


IZMO - An unknown MicroCap 3 yrs back. Now, while being ~10X, below images SELF-EXPLANATORY!



Proud to Publish my Case Series in “AMERICAN JOURNAL OF CASE REPORTS”, amjcaserep.com/abstract/index… which carry 3 “WORLD’s FIRST-ever” to be reported in Medical Literature. 1.World’s 1st documented case of simultaneous Coronary artery Endarterectomy (CAE) + Pericardiectomy. Furthermore, this was done in a patient with very low EF 20-25% - Discharged on post operative 2nd day. 2.Emergency CABG, within 12 hrs of CAG - Discharged on post operative 2nd day, 1st such case documented in medical literature. 3.CABG in Single Kidney patient with borderline renal function S.Creat 1.7 - Discharged on post operative 2nd day, again 1st such case documented in medical literature. All 3 patients with successful 1 year follow up, at the time of submitting the article and now 17 months successful follow up till date 🙏🙏







Very Humbling for me as invaluable Blessings from My Dear Patients pour 🙏🙏 Home grown/home made tokens of gratitude such as these overwhelm. Truly Grateful for all the Love 🙏🙏





